

Jennifer M Trujillo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1388594/publications.pdf>

Version: 2024-02-01

32
papers

1,032
citations

623574

14
h-index

454834

30
g-index

32
all docs

32
docs citations

32
times ranked

1253
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300) Tj ETQq1 1 0.784314 rgBT /Overd Pharmacy, 2022, , 1-12.	0.5	3
2	Clinical review and role of clinical pharmacists in obesity management: An opinion of the endocrine and metabolism practice and research network of the American College of Clinical Pharmacy. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 1469-1484.	0.5	4
3	GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882199732.	1.4	116
4	Endocrine pharmacotherapy education in United States colleges and schools of pharmacy. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 481-489.	0.5	0
5	Part I: PSAP Live: Optimizing care in type 2 diabetes: Evidence-based treatment design and therapy intensification. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 765-768.	0.5	0
6	Oral semaglutide in type 2 diabetes. Journal of Diabetes and Its Complications, 2020, 34, 107520.	1.2	39
7	Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical Guideline. Annals of Internal Medicine, 2020, 173, 813-821.	2.0	60
8	Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 43-60.	0.7	47
9	Effects of Diabetes Numeracy on Glycemic Control and Diabetes Self-Management Behaviors in Patients on Insulin Pump Therapy. Diabetes Therapy, 2019, 10, 1337-1346.	1.2	7
10	Appropriate Titration of Basal Insulin in Type 2 Diabetes and the Potential Role of the Pharmacist. Advances in Therapy, 2019, 36, 1031-1051.	1.3	10
11	Switching basal insulins in type 2 diabetes: practical recommendations for health care providers. Postgraduate Medicine, 2018, 130, 229-238.	0.9	6
12	Anticipatory guidance in type 2 diabetes to improve disease management; next steps after basal insulin. Postgraduate Medicine, 2018, 130, 365-374.	0.9	12
13	Comparison of Usability, Accuracy, Preference, and Satisfaction Among Three Once-Weekly GLP-1 Receptor Agonist Pen Devices. Diabetes Spectrum, 2018, 31, 359-366.	0.4	5
14	Role of combination therapy or coformulation products in treatment of type 2 diabetes. Pharmacy Today, 2018, 24, 50-64.	0.0	2
15	5-alpha-dihydrotestosterone elevations associated with phentermine use. Therapeutic Advances in Endocrinology and Metabolism, 2018, 9, 255-258.	1.4	3
16	Low incidence of gastrointestinal adverse events over time with a fixed-ratio combination of insulin glargine and lixisenatide versus lixisenatide alone. Diabetes, Obesity and Metabolism, 2018, 20, 2690-2694.	2.2	16
17	Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes. Pharmacotherapy, 2017, 37, 481-491.	1.2	34
18	Lixisenatide, a Once-Daily Prandial Glucagon-Like Peptide-1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes. Pharmacotherapy, 2017, 37, 927-943.	1.2	15

#	ARTICLE	IF	CITATIONS
19	Advances in the treatment of type 2 diabetes: impact of dulaglutide. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2016, 9, 125.	1.1	9
20	Cardiovascular Outcomes of New Medications for Type 2 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 749-758.	2.4	7
21	Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness. <i>Therapeutic Advances in Chronic Disease</i> , 2016, 7, 4-17.	1.1	24
22	GLP-1 receptor agonists: a review of head-to-head clinical studies. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2015, 6, 19-28.	1.4	237
23	Impact of Student- Versus Instructor-Directed Case Discussions on Student Performance in a Pharmacotherapy Capstone Course. <i>American Journal of Pharmaceutical Education</i> , 2014, 78, 56.	0.7	11
24	GLP-1 Receptor Agonists for Type 2 Diabetes Mellitus: Recent Developments and Emerging Agents. <i>Pharmacotherapy</i> , 2014, 34, 1174-1186.	1.2	78
25	Albiglutide. <i>Annals of Pharmacotherapy</i> , 2014, 48, 1494-1501.	0.9	53
26	Initial Management of Severe Hyperglycemia in Patients with Type 2 Diabetes: an Observational Study. <i>Diabetes Therapy</i> , 2013, 4, 375-384.	1.2	5
27	Improving Care Transitions: Current Practice and Future Opportunities for Pharmacists. <i>Pharmacotherapy</i> , 2012, 32, e326-37.	1.2	134
28	Understanding who you are and how you work: the role of self-assessment. <i>Currents in Pharmacy Teaching and Learning</i> , 2009, 1, 10-16.	0.4	3
29	A Nutrition Journal and Diabetes Shopping Experience to Improve Pharmacy Students' Empathy and Cultural Competence. <i>American Journal of Pharmaceutical Education</i> , 2009, 73, 37.	0.7	17
30	A Drug Interactions Elective Course. <i>American Journal of Pharmaceutical Education</i> , 2009, 73, 72.	0.7	13
31	Improving glycemic control in medical inpatients: A pilot study. <i>Journal of Hospital Medicine</i> , 2008, 3, 55-63.	0.7	35
32	Development of a Peer Teaching-Assessment Program and a Peer Observation and Evaluation Tool. <i>American Journal of Pharmaceutical Education</i> , 2008, 72, 147.	0.7	27